Anne E. Anderson, MD
Chief, Clinical Neurophysiology
Texas Children's Hospital
Interim Director of the Comprehensive Epilepsy Program, Texas Children's Hospital
Associate Professor, Department of Pediatrics, Baylor College of Medicine
|Baylor College of Medicine||fellowship||Clinical Neurophysiology||1994|
|University of Texas Medical School at Houston||residency||Pediatric Neurology||1993|
|University of Texas Medical Branch||residency||Neurology||1991|
|University of Texas Medical Branch||internship||Psychiatry||1988|
|University of Texas Medical Branch||medical school||Doctor of Medicine||1987|
Comprehensive care of patient’s with epilepsy and neurodevelopmental disorders. Clinical interests are focused on characterization of seizure types and epilepsy in children to optimize the therapeutic strategies. Therapies for our patients with epilepsy include pharmacological, nutritional (ketogenic diet), neurostimulation, and surgical. The goal is to obtain better seizure control or a cure for epilepsy with these therapies. In parallel we emphasize understanding the comorbidities that are associated with epilepsy such as cognitive deficits, psychiatric problems, and others and how to better treat or prevent these problems that are commonly associated with epilepsy.
Working with the epilepsy neurosurgeons for seizure and functional mapping and then surgical treatment of epilepsy.
Characterization of the type of epilepsy.
Identifying and treating associated comorbidities associated with epilepsy.
Super-refractory status epilepticus/FIRES – acute and chronic treatment of this disorder.
Angelman Syndrome – understanding epilepsy and cognitive disorders in these patients.
Tuberosclerosis and other malformations of cortical development – mechanisms of epileptogenesis and novel therapeutic approaches in children with TSC and also in animal models of TSC and other disorders affecting this pathway and leading to brain malformations and epilepsy.
Comorbidities associated with epilepsy, including cognitive deficits and sudden unexpected death in epilepsy (SUDEP).
Super-refractory status epilepticus/FIRES – Understanding the mechanisms associated with this disorder including neuroinflammation and developing novel therapies.
Angelman Syndrome – working on therapies to cure epilepsy and cognitive disorders in animal models of Angelman Syndrome with the goal of bringing these therapies to clinical trials.
Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013 Nov;74(5):679-87. PubMed PMID: 23798472.
Born HA, Dao AT, Levine AT, Lee WL, Mehta NM, Mehra S, Weeber EJ, Anderson AE. Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice. Sci Rep. 2017 Aug 16;7(1):8451. PubMed PMID: 28814801; PubMed Central PMCID: PMC5559514.
Carter AN, Born HA, Levine AT, Dao AT, Zhao AJ, Lee WL, Anderson AE. Wortmannin Attenuates Seizure-Induced Hyperactive PI3K/Akt/mTOR Signaling, Impaired Memory, and Spine Dysmorphology in Rats. eNeuro 2017 May-Jun;4(3)PubMed PMID: 28612047; PubMed Central PMCID: PMC5467399.
Nguyen LH, Anderson AE. mTOR-dependent alterations of Kv1.1 subunit expression occur in the neuronal subset-specific Pten knockout mouse model of cortical dysplasia with epilepsy. Scientific Reports In press.
Patil VV, Guzman M, Carter AN, Rathore G, Yoshor D, Curry D, Wilfong A, Agadi S, Swann JW, Adesina AM, Bhattacharjee MB, Anderson AE. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia. Neuropathology 2016 Apr;36(2):146-56. PubMed PMID: 26381727; PubMed Central PMCID: PMC5458727.
Lai Y, Lawrence W, Wehrens X, Anderson A. Cardiac alterations and increased susceptibility for ventricular tachycardia in a model of acquired epilepsy. Epilepsia Open In press.